

## Press Release

**Revenue up 7% to Rs. 5653 crores in FY23.**

**Vadodara, May 5<sup>th</sup>, 2023**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter and year ended 31<sup>st</sup> March, 2023.

### Financial Highlights

- Net Sales for the quarter at Rs.1406 crores.
- Net Profit for the quarter at Rs.153 crores.
- Net sales for FY23 at Rs. 5653 crores.
- Net profit for FY23 at Rs. 342 crores.

**Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited** said “The USA business continues to remain challenging, however, the Company witnessed topline growth across all other verticals. In particular, the API business outperformed with a 41% growth and Ex-US generics with 33% growth during the quarter. We have started commercialization of products from our injectable and oncology facilities. India Branded Business continues to out perform the market especially on focused products / therapeutic segments.

### Operational Highlights

#### India Branded Business

- India Branded Business grew 9% to Rs. 490 crores in the quarter. Ex of Azithral Branded Business grew 12%
- Specialty segment grew 13% compared to the industry specialty growth of 12% (as per IQVIA)
- Growth in specialty segment was driven by Gynecology, Anti-Diabetic, Ophthalmology & Ortho.
- Acute business grew by 23%, Ex of Azithral it grew by 38% vs representative Industry growth of 28% (as per IQVIA).
- Animal Health business grew 15% over previous year Q4.

## **ALEMBIC PHARMACEUTICALS LIMITED**

### International Business

- US Generics at Rs. 354 crores in the quarter.
- Ex-US International Formulations grew 33% to Rs. 249 Crores in the quarter.
- 7 ANDA approvals received during the quarter; 179 Cumulative ANDA approvals.
- 4 ANDA filings during the quarter; Cumulative ANDA filings at 245.

### API Business

- API business grew 41% at Rs. 313 crores in the quarter.
- 131 cumulative DMF Filings.

The summary of Total Revenue is as under:

(Rs. in Crores)

Particulars	Q4 FY23	Q4 FY22	% Change	FY23	FY22	% Change
<b>Formulation</b>						
USA	354	557	(36%)	1572	1666	(6%)
Ex- US	249	188	33%	852	775	10%
India	490	449	9%	2063	1926	7%
<b>API</b>	313	222	41%	1166	939	24%
<b>Total</b>	<b>1406</b>	<b>1416</b>	<b>(1%)</b>	<b>5653</b>	<b>5306</b>	<b>7%</b>

### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art

### **ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Information about the company can be found at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com);  
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information contact:**

<b>Ajay Kumar Desai</b>  Phone: +91 022- 66953681  Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a>	<b>Mitanshu Shah</b>  Phone: +91 265 – 6637630  Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a>
--	---



**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123